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EDITORIAL

Dr. Conn Lives on: Insights Into Screening and
Genetics of Primary Aldosteronism

T

his issue of Advances in Chronic Kidney Disease features
an old standard, hypertension. This topic is reviewed
periodically. This time, Dr. Kausik Umanath has taken
up the gauntlet to press forward our collective mission
to diagnose and treat this most fundamental medical problem early, accurately, and efﬁciently. In this issue, the variegation of the pathophysiology of hypertension will be
revealed along with its treatments. In Dr. Umanath’s Guest
Editorial, you will see a glimpse of what is contained
within, but ﬁrst, a story.
Several years ago, after a gratifyingly well-cooked lunch,
I explored the shops in Dexter, MI. I ventured into the
Mule Skinner Boot Shop. After initial salutations,
proprietor Billy Conn asked me what I did for a living. I
told him that I, Jerry Yee, was a nephrologist. He parried
and said that he knew what “that” was, but his father,
Jerome W. Conn, had been an endocrinologist. I
exclaimed, “Wow! Your father ﬁrst-described an
aldosteronoma at the University of Michigan.” Impressed
with my riposte and validation of his father’s clinical
acumen, Mr. Conn waxed lyrically about the virtues of
his father-physician who had also described the
mitigation of insulin resistance through weight loss and
acclimatization of man to warm climates, later attributed
to aldosterone-mediated effects. Before we parted ways,
I made a purchase and vowed to return to the shop.
The pathophysiology of Conn’s original description of a
female patient who had been plagued for 7 years with
lower extremity weakness and cramping hands, while
also exhibiting diabetes insipidus (viz., kaliopenic
nephropathy), tetany, hypernatremia, hypokalemic
metabolic alkalosis, and non-edematous hypertension,
stemmed from hyperproduction of the mineralocorticoid
aldosterone that heretofore will be labeled “electrocortin”.1 Subsequent investigation led to the diagnosis
of aldosterone hypersecretion, identiﬁed by urine
biochemical analysis, from a 4-cm adrenal tumor as the
instigator of this surgically remediable form of resistant
hypertension. Since Conn’s seminal observations and
investigations, the knowledge base of primary aldosteronism (PA) has expanded exponentially. However, in

practice, early diagnosis of aldosteronism in resistant
hypertensive patients, when surgical treatment may be
curative, remains vexingly uncommon. In our brief
treatise, as an ode to Jerome Conn, Debbie L. Stein
and I enumerate some barriers to the diagnosis of
aldosteronism and report some of the more recent
biomolecular ﬁndings regarding this disorder that
produces difﬁcult-to-treat high blood pressure.
PA is the most common cause of secondary hypertension
and affects 3–20% of hypertensive patients.2 PA is more
likely present in patients with severe or resistant hypertension. PA is treatable and potentially curable. Consequently,
PA is an important secondary form of hypertension that
should be excluded. Patients with PA have an increased
risk of cardiovascular disease, atrial ﬁbrillation, chronic
kidney disease, and cardiovascular death compared with
individuals with essential hypertension and equivalent
blood pressure elevations.3-6
PA should be suspected in the following clinical
scenarios: new-onset hypertension that is frequently
difﬁcult to control, recent exacerbation of hypertension in
a patient with previously well-controlled blood pressure,
history of leg cramps, or unprovoked hypokalemia.
However, despite declarations in numerous textbooks
regarding PA as a hypokalemic hypertensive disorder,
less than 50% of patients have hypokalemia. In actuality,
normokalemia is common, and when present, should not
deter evaluations for PA, detection of an incidental adrenal
adenoma, or probing the family history for aldosteronism.
Classically, PA is diagnosed by initially acquiring
plasma renin activity (PRA) and plasma aldosterone
concentrations (PACs). If plasma renin is suppressed
(usually ,1 ng/ml/hour) and aldosterone levels are at
least .15 ng/dL, with an aldosterone-to-renin ratio
(ARR) . 20–30, further workup is warranted. Subsequent
conﬁrmatory testing was typically called for before
Ó 2019 by the National Kidney Foundation, Inc. All rights reserved.
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proceeding to more invasive testing. However, recent
guidance from the Endocrine Society no longer
recommends conﬁrmatory testing in patients with
spontaneous hypokalemia, plasma renin concentrations
below detection levels, and PACs .20 ng/dL.7 Patients
meeting these criteria may proceed directly to imaging
studies. ARR screening is optimally conducted in patients
ingesting an unrestricted sodium diet and those who are
normokalemic. As required, potassium should be repleted
until serum potassium concentrations are within the
normal range. Mineralocorticoid-receptor antagonists
should be withdrawn for no less than 4 weeks before
ARR screenings.
The ARR can be conﬁdently interpreted in many cases
despite the effects of onboard medications and/or other
suboptimal conditions of testing. Notably, the “washout”
of all antihypertensive medications that potentially
interfere with interpretation of ARRs is only feasible in
patients with mild hypertension. Some medications that
have minimal obfuscating effects on the ARR include
sustained-release verapamil, hydralazine, prazosin,
doxazosin, and terazosin. Once a biochemical diagnosis
is established, all patients should undergo an initial
adrenal computed tomography imaging study as an
initial step before proceeding to conﬁrmatory adrenal
vein sampling. The latter is considered if and only if
adrenal surgery is a feasible treatment option.
DIRECT RENIN CONCENTRATION VS PLASMA RENIN
ACTIVITY
There are an increased number of laboratories measuring
direct renin concentration (DRC) as an alternative to
PRA. The DRC assay provides several advantages
compared with PRA. Speciﬁcally, DRCs are less laborand time-intensive procedures and have shorter
turnaround times, better reproducibility, and greater ease
of standardization.8 The calculation of the ratio of
aldosterone-to-direct renin concentration (ADRR) may be
employed as a screening test for PA instead of the ARR.
The ADRR is also termed the plasma aldosterone–to–direct
renin concentration ratio (PAC/DRC). Numerous conversion factors have been proposed in an effort to generate
clinically meaningful and stable cutoffs between assays.
Nevertheless, it is uncertain whether an interchangeable
relationship exists, particularly because PRAs and DRCs
are biologically distinct entities.7-9
The correlation between DRC and PRA is generally
good, except when PRAs are ,1 ng/ml/hour, which
corresponds to the most relevant PA clinical screening
scenario.7 In a recently introduced and already commonly
used automated DRC assay, the conversion factor is 12.
Numerous factors affect PAC, DRC, PRA activity,
and calculated ratios. However, these effects are
generally similar for DRC and PRA, aside from a few
clinical situations, including pregnancy and estrogen
administration. Administration of oral contraceptives
increases angiotensinogen with subsequently low PRA/
DRCs. In congestive hepatopathy, there is low
angiotensinogen production, with consequently high

DRCs and low PRAs.9 Brieﬂy, exert caution when interpreting these values in particular clinical circumstances.
The diagnostic efﬁciency of PAC/DRC has varied in
studies, and no general consensus exists concerning the
impact of antihypertensives on this ratio. A recent
meta-analysis included 9 studies involving 974
participants and revealed an overall sensitivity of 0.89
(95% conﬁdence interval [CI], 0.84 to 0.93), speciﬁcity of
0.96 (95% CI, 0.95 to 0.98), area under the curve of 0.985,
and diagnostic odds ratio for ADRR of 324.10 The
associated meta–regression analysis revealed that the
antihypertensive status affects the ADRR and may
account for the heterogeneity (P ¼ 0.03). Principally
speaking, antihypertensive drug therapy in PA may
interfere with the interpretation of ADRRs. In a subgroup
analysis of patients who discontinued antihypertensive
medications, the ADRR had a sensitivity of 0.99 (95%
CI, 0.95 to 1.00) and speciﬁcity of 0.98 (95% CI, 0.96 to
0.99).9 This study established the ADRR as a reliable
screening assay for aldosteronism.
Another study from Poland included 62 patients with
suspicion for PA and 35 healthy volunteers.9 All
participants had PACs, DRCs, and PRAs measured after
a night’s rest and again after walking for 2 hours.
Correlations of ARR with ADRR in the supine position
were r ¼ 0.9162 and r2 ¼ 0.8165 (P , 0.01). Corresponding
values in the upright position were r ¼ 0.7765 and
r2 ¼ 0.9153 (P , 0.01). Cutoff values for ARRs and ADRRs
$100 represented the highest speciﬁcity (99%) for the
diagnosis of PA. However, quite acceptable speciﬁcity
and sensitivity of $80% and 100%, respectively, were
recorded at ratios $30.
Another population-based study was conducted in
Canada with the goal of establishing an ARR cutoff
during the transition from PRA to DRC assays.8 In
Calgary, DRC testing replaced the PRA for routine testing
in 2014; 4301 participants who received testing between
January 2012 and November 2015 were included. During
the initial portion of the study using PRAs and locally
validated cutoff values, 4.9% of screenees were
classiﬁed as highly probable cases of PA, 10.4% probable,
and 28.9% possible. ADRRs were subsequently
determined. A highly probable PA case corresponded to a
cutoff level of .100 pmol L21 mIU21 L21 with
hypokalemia. A probable case corresponded to a cutoff level
of .100 pmol L21 mIU21 L21 and a possible case to .35
pmol L21 mIU21 L21. In contrast, cutoffs derived using a
conversion factor resulted in signiﬁcantly higher cutoffs
and the potential for missed cases. Based on their local experience, the authors suggested that it may be preferable to use
large-population data to establish cutoff values rather than
simply applying conventional direct-method comparisons.
This data-driven approach would lead to fewer falsenegative results, i.e., greater sensitivity.8
In summary, the use of DRCs and ADRRs as opposed to
classical PRAs and ARRs remains problematic because
standardized conversion methodologies do not work
well when renin is suppressed—the clinical scenario
most relevant during screening for PA. As feasible, health
care providers evaluating patients for possible PA should
Adv Chronic Kidney Dis. 2019;26(2):81-84
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rely on local experience and continue to order PRAs and
ARRs until issues surrounding DRCs and ADRRs are
clariﬁed.
GENETIC ASSOCIATIONS OF PRIMARY
ALDOSTERONISM
Somatic and germline mutations have been identiﬁed in
several genes in aldosterone-producing adenomas
(APAs) and familial hyperaldosteronism. Somatic
mutations are present in approximately 50% of patients
with aldosterone-producing adenomas. These mutations
include KCNJ5, ATP1A1, ATP2B3, and CACNA1D. These
gene alterations have accordingly provided insights into
mechanisms of dysregulated aldosterone production.11
Most of the mutations activate the intracellular signaling
pathway that normally regulates aldosterone production.
As a common ﬁnal pathway, all the described gene
mutations, germline or somatic, increase intracellular
calcium concentrations and trigger increased aldosterone
production and cellular proliferation.
The ﬁrst of these somatic mutations was identiﬁed in 2011
during whole exome sequencing of surgically resected
APAs. Genetic sequences from the tumor were aligned
with native DNA from the same patient to identify somatic
DNA changes that induced transformation of normal adrenal tissue into an APA.12 Somatic mutation of a single gene
KCNJ5, which encodes an inwardly rectifying potassium
channel Kir 3.4, was established in 8 of 22 APAs examined.13 A genomic mutation in a family previously reported to have a familial form of aldosteronism distinct
from glucocorticoid-remediable aldosteronism (GRA)
was also identiﬁed.
Three of the loci of the KCNJ5 mutations (i.e., G151 R,
L168 R, and T158 A) were localized to the region encoding
the selectivity ﬁlter of this potassium channel. These
mutations promoted sodium conductance through this
normally sodium-resistant channel. The increased sodium
conductance and ensuing cell depolarization enhanced
intracellular calcium entry, a potent signal for aldosterone
production and cell proliferation.14 KCNJ5 mutations are
more common in females and younger patients. This mutation is more likely associated with higher PACs and propensity for resistant hypertension.15
Further investigations, using a similar approach have
led to the identiﬁcation of somatic gene mutations of
ATP1A1 (encodes a Na1/K1 ATPase alpha-1 subunit)
and ATP2B3 (encodes Ca21-ATPase isoform 3) in,
respectively, 5.2 and 1.6% of 308 APAs studied.16 These
mutations are more commonly found in male patients
with APAs. Notably, these mutations are also associated with increased PACs and lower potassium concentrations than individuals with mutation-negative
adenomas.
Within resected APAs, somatic mutations have been
identiﬁed in CACNA1D, which encodes the alpha-1
subunit of CaV1.3, a voltage-dependent L-type Ca
channel.17 CACNA1D subunit mutations induce a shift
of voltage-dependent gating to more negative voltages,
thereby suppressing calcium-current inactivation, i.e.,
increasing currents. CACNA1D mutations have also

been shown to be present in two children with a novel
syndrome of PA and epilepsy.18 CACNA1D mutation
has been shown to be present in older, male patients.
The tumors are typically smaller and are often not
visualized by conventional imaging techniques. Among
black patients with APAs, a large proportion (89%) has
an aldosterone-driving mutation.11 In a study of 73
tumors from 79 black patients with PA, 65 tumors (89%)
harbored an aldosterone-driving mutation. The most
prevalent genetic alteration by next-generation
sequencing was CACNA1D (42%), trailed closely by
KCNJ5 mutations (34%). ATP1A1 (8%) and ATP2B3
mutations (4%) were less frequent.11
In conclusion, although we acknowledge that somatic
mutations are present in at least 50% of APAs, genetic
sequencing of APAs is still a research tool, and its clinical
use is yet unknown. Despite that we have discerned the
various somatic mutations more likely to occur in
different genders and racial groups, optimized protocols
by which these observations can be reasonably applied
to personalized medicine are enigmatic. Currently,
treatment does not differ whether a somatic mutation is
present or not.
It is now more than 6 decades since Conn’s original
description of PA. Our knowledge base has been
enhanced by molecular science, and screening for PA is
improved. Plus, we have more antihypertensive
medication choices, although mineralocorticoid-receptor
antagonism in PA remains medicamentum electio. We
must endeavor to diagnose this disorder earlier to effect
surgical cures, where applicable, and prevent
cardiovascular complications. After all, it was Dr. Conn’s
tenet that up to 20% of individuals with essential
hypertension might actually have PA.
Reason tells us that we must acquiesce in a vague
kind of way to the statement that every fact has a
potential usefulness. In the meanwhile, it is regarded
as background, available to all who choose to use it.
Are there any of us capable of evaluating which fact,
when eventually correlated with others, will have
the greatest impact upon the lives of men? The
answer is "No."19
—Jerome (“Jerry”) W. Conn.
Debbie L. Stein, MD
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Renal Division
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